secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040956
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Q2 net loss $35.2M, CFO resigns; cash sustains into 2025
-------------------------------------------------------------------

- Net loss of $35.2M for Q2 2023 vs $26.5M in Q2 2022; R&D expenses $29.1M.
- Cash and marketable securities $207.6M at June 30, expected to fund operations into 2025.
- CFO Ajim Tamboli resigned; no replacement announced yet.
- Initial Phase 1/2 data for MRT-2359 expected H2 2023; IND for MRT-6160 expected H1 2024.
- FDA Orphan Drug Designation for MRT-2359 for small cell lung cancer received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023040956/0000950170-23-040956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023040956/glue-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer